Skip to main content
SpringerLink
Log in

Pharmacologic Management of Patients with Neurologic Disorders

  • Chapter
  • First Online:
Contemporary Dental Pharmacology

  • 1001 Accesses

Abstract

Neurologic and psychiatric disorders encompass a diverse range of disabling conditions. Collectively these diseases are increasingly recognized as disorders of the brain’s neural connections. Brain disorders are currently estimated to affect as many as 1.5 billion people worldwide—a number that is expected to grow as life expectancy increases (Gooch et al., Ann Neurol 81:479–484, 2017). Treatment of these chronic conditions involves long-term use of multiple pharmacologic agents, raising the concern of side effects and possible drug interactions with medications used during the delivery of dental care. There is much overlap between the types of medications used to treat both neurologic and psychiatric diseases. Appropriate preoperative assessment of dental patients should always include obtaining a thorough medical history that includes a current complete list of medications. It is incumbent on the oral healthcare practitioner that an analysis of possible drug interactions be done prior to the administration or prescription of any drugs used during the provision of dental care. This chapter provides an update of the current drug therapies used for patients with psychiatric diagnoses as well as Parkinson’s disease, Alzheimer’s disease, and seizure disorders and discusses potential drug interactions of clinical importance to the oral healthcare provider.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aarsland D, Larsen JP, Lim NG, Janvin C, Karlsen K, Tandberg E, Cummings JL. Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1999;67(4):492–6.

    Article  PubMed  PubMed Central  Google Scholar 

  • Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord. 2009;24(15):2175–86.

    Article  PubMed  PubMed Central  Google Scholar 

  • Abdallah C. Considerations in perioperative assessment of valproic acid coagulopathy. J Anaesthesiol Clin Pharmacol. 2014;30(1):7.

    Article  PubMed  PubMed Central  Google Scholar 

  • Alda M. Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics. Mol Psychiatry. 2015;20(6):661.

    Article  PubMed  PubMed Central  Google Scholar 

  • Alz.org. Alzheimer’s disease & dementia|Alzheimer’s Association. [online]. 2018. https://www.alz.org/alzheimers_disease_what_is_alzheimers.asp. Accessed 28 May 2018.

  • Alzheimer’s Association. 2018 Alzheimer’s disease facts and figures. Alzheimers Dement. 2018;14(3):367–429.

    Article  Google Scholar 

  • Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(6):811.

    Article  PubMed  Google Scholar 

  • Anon. [online]. 2018. http://www.ninds.nih.gov/disorders/parkinsons_disease/parkinsons_disease.htm. Accessed 29 May 2018.

  • Balakrishnan R, Ebenezer VI. Contraindications of vasoconstrictors in dentistry. Biomed Pharmacol J. 2013;6(2):409–14.

    Article  Google Scholar 

  • Baldessarini RJ. Drug therapy of depression and anxiety disorders. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. New York: McGraw-Hill; 2006. p. 429–60.

    Google Scholar 

  • Bauer MS, Mitchner L. What is a “mood stabilizer”? An evidence-based response. Am J Psychiatr. 2004;161(1):3–18.

    Article  PubMed  Google Scholar 

  • Becker DE. Psychotropic drugs: implications for dental practice. Anesth Prog. 2008;55(3):89–99.

    Article  PubMed  PubMed Central  Google Scholar 

  • Bentué-Ferrer D, Tribut O, Polard E, Allain H. Clinically significant drug interactions with cholinesterase inhibitors. CNS Drugs. 2003;17(13):947–63.

    Article  PubMed  Google Scholar 

  • Bhat NP, Preethishree P. Depression and its pharmacological management: a critical review. J Drug Deliv Therap. 2015;5(4):54–60.

    Google Scholar 

  • Bomasang-Layno E, Fadlon I, Murray AN, Himelhoch S. Antidepressive treatments for Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2015;21(8):833–42.

    Article  PubMed  Google Scholar 

  • Brodie MJ, Besag F, Ettinger AB, Mula M, Gobbi G, Comai S, Aldenkamp AP, Steinhoff BJ. Epilepsy, antiepileptic drugs, and aggression: an evidence-based review. Pharmacol Rev. 2016;68(3):563–602.

    Article  PubMed  PubMed Central  Google Scholar 

  • Brown RS, Rhodus NL. Epinephrine and local anesthesia revisited. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100(4):401–8.

    Article  PubMed  Google Scholar 

  • Casey DA. Pharmacotherapy of neuropsychiatric symptoms of dementia. P T. 2015;40(4):284–7.

    PubMed  PubMed Central  Google Scholar 

  • Catalani B, Hamilton CS, Herron EW, Urman RD, Fox CJ, Kaye AD. Psychiatric agents and implications for perioperative analgesia. Best Pract Res Clin Anaesthesiol. 2014;28(2):167–81.

    Article  PubMed  Google Scholar 

  • Chen JJ. Parkinson disease: a summary of recent evidence-based medicine reviews. Ment Health Clin. 2012;2(2):25–31.

    Article  Google Scholar 

  • Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3):279–86.

    Article  PubMed  Google Scholar 

  • Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670–83.

    Article  PubMed  Google Scholar 

  • Defilippi JL, Crismon ML. Drug interactions with cholinesterase inhibitors. Drugs Aging. 2003;20(6):437–44.

    Article  PubMed  Google Scholar 

  • Epilepsy Foundation. About epilepsy: the basics. (online). 2018. https://www.epilepsy.com/learn/about-epilepsy-basics. Accessed 28 May 2018.

  • Fennema J, Petrykiv S, de Jonge L, Arts M. Efficacy and safety of antidepressants as analgesics in chronic pain: a review. Eur Psychiatry. 2017;41:S234.

    Article  Google Scholar 

  • Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpää M, Hansson P, Jensen TS, Kamerman PR. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–73.

    Article  PubMed  PubMed Central  Google Scholar 

  • Fishbain D. Evidence-based data on pain relief with antidepressants. Ann Med. 2000;32(5):305–16.

    Article  PubMed  Google Scholar 

  • Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, Lagae L, Moshé SL, Peltola J, Roulet Perez E, Scheffer IE. Operational classification of seizure types by the international league against epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):522–30.

    Article  PubMed  Google Scholar 

  • Friedlander AH, Marder SR. The psychopathology, medical management and dental implications of schizophrenia. J Am Dent Assoc. 2002;133(5):603–10.

    Article  PubMed  Google Scholar 

  • Friedlander AH, Norman DC. Late-life depression: psychopathology, medical interventions, and dental implications. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;94(4):404–12.

    Article  PubMed  Google Scholar 

  • Friedlander AH, Mahler M, Norman KM, Ettinger RL. Parkinson disease: systemic and orofacial manifestations, medical and dental management. J Am Dent Assoc. 2009;140(6):658–69.

    Article  PubMed  Google Scholar 

  • Garrett AR, Hawley JS. SSRI-associated bruxism: a systematic review of published case reports. Neurol Clin Pract. 2018;8(2):135–41.

    Article  PubMed  PubMed Central  Google Scholar 

  • Gauthier S, Cummings J, Ballard C, Brodaty H, Grossberg G, Robert P, Lyketsos C. Management of behavioral problems in Alzheimer’s disease. Int Psychogeriatr. 2010;22(3):346–72.

    Article  PubMed  Google Scholar 

  • Giron MS, Forsell Y, Bernsten C, Thorslund M, Winblad B, Fastbom J. Psychotropic drug use in elderly people with and without dementia. Int J Geriatr Psychiatry. 2001;16(9):900–6.

    Article  PubMed  Google Scholar 

  • Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, Bare M, Bleck T, Dodson WE, Garrity L, Jagoda A. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American Epilepsy Society. Epilepsy Curr. 2016;16(1):48–61.

    Article  PubMed  PubMed Central  Google Scholar 

  • Gooch CL, Pracht E, Borenstein AR. The burden of neurological disease in the United States: a summary report and call to action. Ann Neurol. 2017;81(4):479–84.

    Article  PubMed  Google Scholar 

  • Griffin CE III, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system–mediated effects. Ochsner J. 2013;13(2):214–23.

    PubMed  PubMed Central  Google Scholar 

  • Gubbins PO, Heldenbrand S. Clinically relevant drug interactions of current antifungal agents. Mycoses. 2010;53(2):95–113.

    Article  PubMed  Google Scholar 

  • Han JY, Besser LM, Xiong C, Kukull WA, Morris JC. Cholinesterase inhibitor use and cognitive decline in mild cognitive impairment and mild dementia due to Alzheimer disease. Alzheimers Dement. 2017;13(7):P1054.

    Google Scholar 

  • Hashimoto R, Hough C, Nakazawa T, Yamamoto T, Chuang DM. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem. 2002;80(4):589–97.

    Article  PubMed  Google Scholar 

  • Kennedy WK, Jann MW, Kutscher EC. Clinically significant drug interactions with atypical antipsychotics. CNS Drugs. 2013;27(12):1021–48.

    Article  PubMed  Google Scholar 

  • Kishi T, Matsunaga S, Oya K, Nomura I, Ikuta T, Iwata N. Memantine for Alzheimer’s disease: an updated systematic review and meta-analysis. J Alzheimers Dis. 2017;60(2):401–25.

    Article  PubMed  Google Scholar 

  • Kumar A, Singh A. A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep. 2015;67(2):195–203.

    Article  PubMed  Google Scholar 

  • Kyrios M. Anxiety disorders in primary care. In: Emmelkamp P, Ehring T, editors. The Wiley handbook of anxiety disorders. Hoboken: Wiley; 2014. p. 58–68.

    Chapter  Google Scholar 

  • Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2008;27(1):31–40.

    Article  PubMed  Google Scholar 

  • Lopez OL, Živković S, Smith G, Becker JT, Meltzer CC, DeKosky ST. Psychiatric symptoms associated with cortical-subcortical dysfunction in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci. 2001;13(1):56–60.

    Article  PubMed  Google Scholar 

  • Löscher W, Klitgaard H, Twyman RE, Schmidt D. New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov. 2013;12(10):757.

    Article  PubMed  Google Scholar 

  • Malamed SF. Pharmacology of vasoconstrictors. In: Malamed SF, editor. Handbook of local anesthesia-E-book. London: Elsevier Health Sciences; 2014. p. 39–52.

    Google Scholar 

  • Mansour A, Pearce M, Johnson B, Sey MS, Oda N, Collegala N, Krishnadev U, Bhalerao S. Which patients taking SSRIs are at greatest risk of bleeding? J Fam Pract. 2006;55(3):206–8.

    PubMed  Google Scholar 

  • Manu P, Flanagan RJ, Ronaldson KJ, editors. Life-threatening effects of antipsychotic drugs. London: Academic Press; 2016.

    Google Scholar 

  • Melvin CL, Carey TS, Goodman F, Oldham JM, Williams JW Jr, Ranney LM. Effectiveness of antiepileptic drugs for the treatment of bipolar disorder: findings from a systematic review. J Psychiatr Pract. 2008;14:9–14.

    Article  PubMed  Google Scholar 

  • Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, Bienfait K, Dicke A. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2009;72(10):886–92.

    Article  PubMed  PubMed Central  Google Scholar 

  • Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012;17(12):1206.

    Article  PubMed  Google Scholar 

  • Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, Shulman LM, Gronseth G, Weiner WJ. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review) report of the quality standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):996–1002.

    Article  PubMed  Google Scholar 

  • Moodley DS. Local anaesthetics in dentistry-part 3: vasoconstrictors in local anaesthetics. S Afr Dent J. 2017;72(4):176–8.

    Google Scholar 

  • Mulsant BH, Sink K, Holden K, Yaffe K. Pharmacotherapy provides minimal improvements in the neuropsychiatric symptoms of dementia. Evid Based Ment Health. 2005;8(3):83.

    Article  PubMed  Google Scholar 

  • Nimh.nih.gov. NIMH: mental illness. (online). 2018a. http://www.nimh.nih.gov/health/statistics/prevalence/any-mental-illness-ami-among-adults.shtml. Accessed 1 Jun 2018.

  • Nimh.nih.gov. NIMH: schizophrenia. (online). 2018b. https://www.nimh.nih.gov/health/statistics/schizophrenia.shtml. Accessed 26 May 2018.

  • Nimh.nih.gov. NIMH: bipolar disorder. (online). 2018c. http://www.nimh.nih.gov/health/statistics/prevalence/bipolar-disorder-among-adults.shtml. Accessed 26 May 2018.

  • Nimh.nih.gov. NIMH: major depression. (online). 2018d. http://www.nimh.nih.gov/health/statistics/prevalence/major-depression-among-adults.shtml. Accessed 26 May 2018.

  • Nimh.nih.gov. NIMH: any anxiety disorder. (online). 2018e. http://www.nimh.nih.gov/health/statistics/prevalence/any-anxiety-disorder-among-adults.shtml. Accessed 26 May 2018.

  • Noetzli M, Eap CB. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer’s disease. Clin Pharmacokinet. 2013;52(4):225–41.

    Article  PubMed  Google Scholar 

  • Nussbaum RL, Ellis CE. Alzheimer’s disease and Parkinson’s disease. N Engl J Med. 2003;348(14):1356–64.

    Article  PubMed  Google Scholar 

  • Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, Breitner JC, Bruce ML, Caine ED, Cummings JL, Devanand DP, Krishnan KR. Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry. 2002;10(2):125–8.

    Article  PubMed  Google Scholar 

  • Orgeta V, Tabet N, Nilforooshan R, Howard R. Efficacy of antidepressants for depression in Alzheimer’s disease: systematic review and meta-analysis. J Alzheimers Dis. 2017;58(3):725–33.

    Article  PubMed  PubMed Central  Google Scholar 

  • Ozeki Y, Fujii K, Kurimoto N, Yamada N, Okawa M, Aoki T, Takahashi J, Ishida N, Horie M, Kunugi H. QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2010;34(2):401–5.

    Article  Google Scholar 

  • Pasqualetti G, Tognini S, Calsolaro V, Polini A, Monzani F. Potential drug–drug interactions in Alzheimer patients with behavioral symptoms. Clin Interv Aging. 2015;10:1457.

    PubMed  PubMed Central  Google Scholar 

  • Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003;2(8):473–81.

    Article  PubMed  Google Scholar 

  • Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61(3):246–55.

    Article  PubMed  Google Scholar 

  • Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583–90.

    Article  PubMed  Google Scholar 

  • Rabkin JU, Quitkin F, Harrison WI, Tricamo E, McGRATH PA. Adverse reactions to monoamine oxidase inhibitors. Part I. A comparative study. J Clin Psychopharmacol. 1984;4(5):270–8.

    Article  PubMed  Google Scholar 

  • Robbins MR. Dental management of special needs patients who have epilepsy. Dent Clin North Am. 2009;53(2):295–309.

    Article  PubMed  Google Scholar 

  • Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer’s disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatr. 2005;162(11):2022–30.

    Article  PubMed  Google Scholar 

  • Salerno SM, Browning R, Jackson JL. The effect of antidepressant treatment on chronic back pain: a meta-analysis. Arch Intern Med. 2002;162(1):19–24.

    Article  PubMed  Google Scholar 

  • Sansone RA, Sansone LA. Tramadol: seizures, serotonin syndrome, and coadministered antidepressants. Psychiatry (Edgmont). 2009;6(4):17.

    Google Scholar 

  • Saraghi M, Golden LR, Hersh EV. Anesthetic considerations for patients on antidepressant therapy—part I. Anesth Prog. 2017;64(4):253–61.

    Article  PubMed  PubMed Central  Google Scholar 

  • Schmidt D, Schachter SC. Drug treatment of epilepsy in adults. BMJ. 2014;348:g254.

    Article  PubMed  Google Scholar 

  • Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191–210.

    Article  PubMed  Google Scholar 

  • Selkoe DJ, Schenk D. Alzheimer’s disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol. 2003;43(1):545–84.

    Article  PubMed  Google Scholar 

  • Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? Am J Med. 2006;119(2):113–6.

    Article  PubMed  Google Scholar 

  • Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293(5):596–608.

    Article  PubMed  Google Scholar 

  • Substance Abuse and Mental Health Services Administration. Results from the 2014 National Survey on Drug Use and Health: mental health findings, NSDUH series H-50, HHS publication no. (SMA) 15-4927. Rockville: Substance Abuse and Mental Health Services Administration; 2015. http://www.samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.pdf. Accessed 1 April 2018.

  • Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review) report of the quality standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):968–75.

    Article  PubMed  Google Scholar 

  • Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm. 2017;124(8):901–5.

    Article  PubMed  Google Scholar 

  • Vasudev K, Keown P, Gibb I, McAllister-Williams RH. Hematological effects of valproate in psychiatric patients: what are the risk factors? J Clin Psychopharmacol. 2010;30(3):282–5.

    Article  PubMed  Google Scholar 

  • Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer’s disease. Neuron. 2004;44(1):181–93.

    Article  PubMed  Google Scholar 

  • Wang J, Yu JT, Wang HF, Meng XF, Wang C, Tan CC, Tan L. Pharmacological treatment of neuropsychiatric symptoms in Alzheimer’s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2015;86(1):101–9.

    Article  PubMed  Google Scholar 

  • Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol. 2011;26(1):1.

    Article  Google Scholar 

  • Yagiela JA. Adverse drug interactions in dental practice: interactions associated with vasoconstrictors. J Am Dent Assoc. 1999;130(5):701–9.

    Article  PubMed  Google Scholar 

  • Zack MM, Kobau R. National and state estimates of the numbers of adults and children with active epilepsy-United States, 2015. Morb Mortal Wkly Rep. 2017;66(31):821–5.

    Article  Google Scholar 

  • Zhuo C, Jiang R, Li G, Shao M, Chen C, Chen G, Tian H, Li J, Xue R, Jiang D. Efficacy and tolerability of second and third generation anti-epileptic drugs in refractory epilepsy: a network meta-analysis. Sci Rep. 2017;7(1):2535.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dental Medicine, NYU Winthrop Hospital, Mineola, NY, USA

    Miriam R. Robbins

  2. Department of Oral and Maxillofacial Pathology, Radiology and Medicine, NYU College of Dentistry, New York, NY, USA

    Miriam R. Robbins

Authors
  1. Miriam R. Robbins
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Miriam R. Robbins .

Editor information

Editors and Affiliations

  1. UTHealth School of Dentistry, Houston, TX, USA

    Arthur H. Jeske

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Robbins, M.R. (2019). Pharmacologic Management of Patients with Neurologic Disorders. In: Jeske, A. (eds) Contemporary Dental Pharmacology. Springer, Cham. https://doi.org/10.1007/978-3-319-99852-7_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-99852-7_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-99851-0

  • Online ISBN: 978-3-319-99852-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation